title: Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators.
abstract: The NFKB-2 gene codes for an NF-kappa B-related transcription factor containing rel-polyG-ankyrin domains. Chromosomal rearrangements of the NFKB-2 locus have been found in various types of lymphoid neoplasms, suggesting that they may contribute to lymphomagenesis. Rearrangements cluster within the 3'-terminal ankyrin-encoding domain of the NFKB-2 gene and lead to the production of C-terminally truncated proteins which, in some cases, are fused to heterologous protein domains. In order to determine the functional consequences of these alterations, we have analyzed the subcellular localization, DNA binding, and transcriptional activity of two representative tumor-associated mutants in which the ankyrin domain is either terminally truncated (NFKB-2p85) or truncated and joined to an out-of-frame immunoglobulin C alpha domain (lyt-10C alpha). Immunofluorescence studies performed on cells transfected with p85 or lyt-10C alpha expression vectors showed that both the abnormal proteins were constitutively localized in the nucleus. Immunoprecipitation analysis of UV-cross-linked DNA-protein adducts showed that p85 can bind kappa B sites in its unprocessed form. Cotransfection of p85 or lyt-10C alpha expression vectors with kappa B-driven reporter plasmids showed that both p85 and lyt-10C alpha have retained the ability to mediate transcriptional activation via heterodimerization with Rel-Ap65 but have lost the transrepression activity associated with homodimeric DNA binding. Furthermore, both p85 and lyt-10C alpha were capable of independent transactivation of kappa B-reporter genes and this activity could not be further stimulated by Bcl-3. These abnormal proteins may contribute to lumphomagenesis by determining a constitutive activation of the NF-kappa B system and, in particular, of NFKB-2 target genes.
authors.affiliation: Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
authors.forename: C C
authors.initials: CC
authors.lastname: Chang
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: L
authors.initials: L
authors.lastname: Lombardi
authors.forename: A
authors.initials: A
authors.lastname: Neri
authors.forename: R
authors.initials: R
authors.lastname: Dalla-Favera
mesh_terms: D017487:Ankyrins / Q000235:genetics; D000081242:B-Cell Lymphoma 3 Protein; D002451:Cell Compartmentation; D004268:DNA-Binding Proteins / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D015321:Gene Rearrangement; D008223:Lymphoma / Q000209:etiology / Q000235:genetics*; D008957:Models, Genetic; D016328:NF-kappa B / Q000235:genetics* / Q000378:metabolism; D052003:NF-kappa B p52 Subunit; D011485:Protein Binding; D011487:Protein Conformation; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism; D015534:Trans-Activators / Q000235:genetics* / Q000378:metabolism; D014157:Transcription Factors; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured
chemical_list: D017487:Ankyrins; D000081242:B-Cell Lymphoma 3 Protein; D004268:DNA-Binding Proteins; D016328:NF-kappa B; D052003:NF-kappa B p52 Subunit; D011518:Proto-Oncogene Proteins; D015534:Trans-Activators; D014157:Transcription Factors